Literature DB >> 20546830

Protective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes.

Thomas A Penfound1, Edna Y Chiang, Elwaleed A Ahmed, James B Dale.   

Abstract

The amino terminal region of group A streptococcal M proteins evokes type-specific immunity while the conserved C-repeat epitopes evoke cross-protective immunity against multiple serotypes. The present studies were undertaken to compare the protective efficacy of vaccines containing either type-specific (hexavalent vaccine) or conserved C-repeat (J14 vaccine) M protein epitopes and to determine if combination vaccines resulted in enhanced levels of protection. Our results indicated that the protective efficacy of the type-specific vaccine was significantly greater than that of J14 and that the addition of J14 to vaccine formulations did not enhance the level of protection achieved with type-specific formulations. Published by Elsevier Ltd.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20546830      PMCID： PMC2906646          DOI： 10.1016/j.vaccine.2010.05.018

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  33 in total

1.  New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population.

Authors:  E R Brandt; K S Sriprakash; R I Hobb; W A Hayman; W Zeng; M R Batzloff; D C Jackson; M F Good
Journal:  Nat Med       Date:  2000-04       Impact factor: 53.440

2.  Studies on immunity to streptococcal infections in man.

Authors:  L W WANNAMAKER; F W DENNY; W D PERRY; A C SIEGEL; C H RAMMELKAMP
Journal:  AMA Am J Dis Child       Date:  1953-09

3.  Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections.

Authors:  Mary A Hall; Steven D Stroop; Mary C Hu; Michael A Walls; Mark A Reddish; David S Burt; George H Lowell; James B Dale
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

4.  Binding of human plasma proteins to Streptococcus pyogenes M protein determines the location of opsonic and non-opsonic epitopes.

Authors:  Charlotta Sandin; Fredric Carlsson; Gunnar Lindahl
Journal:  Mol Microbiol       Date:  2006-01       Impact factor: 3.501

5.  Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments.

Authors:  J B Dale
Journal:  Vaccine       Date:  1999-01       Impact factor: 3.641

Review 6.  The global burden of group A streptococcal diseases.

Authors:  Jonathan R Carapetis; Andrew C Steer; E Kim Mulholland; Martin Weber
Journal:  Lancet Infect Dis       Date:  2005-11       Impact factor: 25.071

7.  Protective immunity evoked by locally administered group A streptococcal vaccines in mice.

Authors:  M S Bronze; D S McKinsey; E H Beachey; J B Dale
Journal:  J Immunol       Date:  1988-10-15       Impact factor: 5.422

8.  Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial.

Authors:  Karen L Kotloff; Mary Corretti; Kathleen Palmer; James D Campbell; Mark A Reddish; Mary C Hu; Steven S Wasserman; James B Dale
Journal:  JAMA       Date:  2004-08-11       Impact factor: 56.272

9.  Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci.

Authors:  D Bessen; V A Fischetti
Journal:  Infect Immun       Date:  1988-10       Impact factor: 3.441

10.  STUDIES ON THE BIOLOGY OF STREPTOCOCCUS : I. ANTIGENIC RELATIONSHIPS BETWEEN STRAINS OF STREPTOCOCCUS HAEMOLYTICUS.

Authors:  A R Dochez; O T Avery; R C Lancefield
Journal:  J Exp Med       Date:  1919-09-01       Impact factor: 14.307
View more
  17 in total

1.  M-protein based vaccine induces immunogenicity and protection from Streptococcus pyogenes when delivered on a high-density microarray patch (HD-MAP).

Authors:  Jamie-Lee S Mills; Cesar M Jayashi Flores; Manisha Pandey; Michael F Good; Simone Reynolds; Christine Wun; Ainslie Calcutt; S Ben Baker; Senthil Murugappan; Alexandra C I Depelsenaire; Jessica Dooley; Paul V Fahey; Angus H Forster
Journal:  NPJ Vaccines       Date:  2020-08-07       Impact factor: 7.344

2.  Protective immunogenicity of group A streptococcal M-related proteins.

Authors:  James B Dale; Shannon E Niedermeyer; Tina Agbaosi; Nicholas D Hysmith; Thomas A Penfound; Claudia M Hohn; Matthew Pullen; Michael I Bright; Daniel S Murrell; Lori E Shenep; Harry S Courtney
Journal:  Clin Vaccine Immunol       Date:  2015-01-28

3.  Cross-reactive immunogenicity of group A streptococcal vaccines designed using a recurrent neural network to identify conserved M protein linear epitopes.

Authors:  Jay A Spencer; Tom Penfound; Sanaz Salehi; Michelle P Aranha; Lauren E Wade; Rupesh Agarwal; Jeremy C Smith; James B Dale; Jerome Baudry
Journal:  Vaccine       Date:  2021-02-26       Impact factor: 3.641

4.  Structure-based design of broadly protective group a streptococcal M protein-based vaccines.

Authors:  James B Dale; Pierre R Smeesters; Harry S Courtney; Thomas A Penfound; Claudia M Hohn; Jeremy C Smith; Jerome Y Baudry
Journal:  Vaccine       Date:  2016-11-24       Impact factor: 3.641

Review 5.  Variation, Indispensability, and Masking in the M protein.

Authors:  Partho Ghosh
Journal:  Trends Microbiol       Date:  2017-08-31       Impact factor: 17.079

6.  Potential coverage of a multivalent M protein-based group A streptococcal vaccine.

Authors:  James B Dale; Thomas A Penfound; Boubou Tamboura; Samba O Sow; James P Nataro; Milagritos Tapia; Karen L Kotloff
Journal:  Vaccine       Date:  2013-01-31       Impact factor: 3.641

7.  A novel live vector group A streptococcal emm type 9 vaccine delivered intranasally protects mice against challenge infection with emm type 9 group A streptococci.

Authors:  Aniela Wozniak; Patricia García; Enrique A Geoffroy; Daniel B Aguirre; Samantha A González; Victoria A Sarno; James B Dale; Francisco J Salazar-Echegarai; Andrea Vera; Susan M Bueno; Alexis M Kalergis
Journal:  Clin Vaccine Immunol       Date:  2014-07-23

Review 8.  Staphylococcal and streptococcal superantigen exotoxins.

Authors:  Adam R Spaulding; Wilmara Salgado-Pabón; Petra L Kohler; Alexander R Horswill; Donald Y M Leung; Patrick M Schlievert
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

9.  Region specific and worldwide distribution of collagen-binding M proteins with PARF motifs among human pathogenic streptococcal isolates.

Authors:  Silvana Reissmann; Christine M Gillen; Marcus Fulde; René Bergmann; Andreas Nerlich; Reena Rajkumari; Kootallur N Brahmadathan; Gursharan S Chhatwal; D Patric Nitsche-Schmitz
Journal:  PLoS One       Date:  2012-01-11       Impact factor: 3.240

10.  Design of Broadly Cross-Reactive M Protein-Based Group A Streptococcal Vaccines.

Authors:  Michelle P Aranha; Thomas A Penfound; Sanaz Salehi; Anne Botteaux; Pierre Smeesters; James B Dale; Jeremy C Smith
Journal:  J Immunol       Date:  2021-08-02       Impact factor: 5.426
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.